MRidium 3870 pump

Search documents
Iradimed (IRMD) Q2 Revenue Jumps 14%
The Motley Fool· 2025-08-02 06:54
Core Insights - Iradimed Corporation reported record revenue and profit for Q2 2025, with revenue of $20.41 million and non-GAAP EPS of $0.49, surpassing analyst expectations and the company's own guidance [1][2][9] Financial Performance - Revenue increased by 14% year-over-year from $17.93 million in Q2 2024 to $20.41 million in Q2 2025 [2][5] - Non-GAAP EPS rose 17% from $0.42 in Q2 2024 to $0.49 in Q2 2025, while GAAP EPS increased 18% from $0.38 to $0.45 [2][6] - Gross profit margin remained stable at 78% [2][6] - Free cash flow decreased by 8% year-over-year to $4.92 million [2][6] Product Performance - MRI-compatible IV infusion pump systems, the largest product group, saw revenue growth of approximately 15.5% compared to Q2 2024 [5] - Patient vital signs monitoring systems grew by approximately 1.3%, while disposables expanded by 14% [5] - Ferro magnetic detection systems experienced the highest growth at 32% compared to Q2 2024 [5] Business Strategy - The company focuses on technological innovation, expanding its installed base, and maintaining regulatory compliance [4] - A new manufacturing facility is nearing completion to meet increasing demand [4][6] Geographic Distribution - Domestic sales accounted for 89% of total revenue, up from 86% a year ago, while international sales remained flat or lower [7] Future Outlook - For Q3 2025, revenue guidance is set between $20.5 million and $20.9 million, with projected non-GAAP EPS of $0.45 to $0.49 [11] - Fiscal 2025 revenue outlook has been raised to $80.0–$82.5 million, with non-GAAP EPS expected between $1.76 and $1.86 [11] - The next-generation MRidium 3870 pump is expected to launch commercially in late 2025 [10]